Segment information
The Group operates in one segment, which is the research, development of innovative women’s reproductive, health and pregnancy therapeutics. The marketing and commercialization of such therapeutics depend, in large part, on the success of the development phase. The Chief Executive Officer of the Company reviews the consolidated statement of operations of the Group on an aggregated basis and manages the operations of the Group as a single operating segment.
The Group currently generates no revenue from the sales of therapeutics products.
The Group’s activities are not affected by any significant seasonal effect.
The geographical analysis of non-current assets is as follows:
|
|
|
As at December 31, |
|
|||||
|
in USD ‘000 |
|
2017 |
|
|
2016 |
|
||
|
Switzerland |
|
|
21,832 |
|
|
|
16,819 |
|
|
USA |
|
|
289 |
|
|
|
— |
|
|
Total non-current assets as at December 31 |
|
|
22,121 |
|
|
|
16,819 |
|
The geographical analysis of operating expenses is as follows:
|
|
|
Year ended December 31, |
|
|||||||||
|
in USD ‘000 |
|
2017 |
|
|
2016 |
|
|
2015 |
|
|||
|
Switzerland |
|
|
63,956 |
|
|
|
30,163 |
|
|
|
19,846 |
|
|
USA |
|
|
3,524 |
|
|
|
— |
|
|
|
— |
|
|
Total operating expenses |
|
|
67,480 |
|
|
|
30,163 |
|
|
|
19,846 |
|